AstraZeneca reports that its rare disease medicine helps some patients with a bone disorder, even though it didn't meet a main goal.

AZN · AstraZeneca Plc

The AI's read

The failed main test weakens the case for efzimfotase alfa. It is the trial's key walking measure in previously untreated adolescents and adults. Other results were encouraging. More treated patients reached a meaningful walking improvement, fatigue improved, and patients with childhood-onset disease showed benefits. Continued improvement also appeared in longer follow-up, but these findings do not erase the main test failure.